Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISTH 2023 | Analyzing response to desmopressin in patients with type 2N von Willebrand disease

Melanie Daniel • 25 Jun 2023
ISTH 2023
Non-Malignant Rare Diseases Von Willebrand Disease Desmopressin

In this video, Melanie Daniel, MD, Lille Hospital University, Lille, France, discusses an analysis evaluating response to desmopressin in patients with type 2N Von Willebrand disease (VWD). Dr Daniel explains that some patients respond poorly to the treatment, and that response was somewhat associated with a patient’s genotype and their factor VIII (FVIII) levels at baseline. This interview took place at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Montréal, Canada.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Melanie Daniel

0:52
Unmet needs and emerging approaches in the treatment of von Willebrand disease
Melanie Daniel • 25 Jun 2023

Related Videos

2:01
The MDT in the new era of gene therapy for hemoglobinopathies
Mattia Algeri • 15 Apr 2024
2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals